Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Smokers with COPD Show a Shift in Energy and Nitrogen Metabolism at Rest and During Exercise.

Holz O, DeLuca DS, Roepcke S, Illig T, Weinberger KM, Schudt C, Hohlfeld JM.

Int J Chron Obstruct Pulmon Dis. 2020 Jan 6;15:1-13. doi: 10.2147/COPD.S217474. eCollection 2020.

2.

Phosphodiesterase inhibitors: history of pharmacology.

Schudt C, Hatzelmann A, Beume R, Tenor H.

Handb Exp Pharmacol. 2011;(204):1-46. doi: 10.1007/978-3-642-17969-3_1. Review.

PMID:
21695634
3.

cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases.

Pullamsetti SS, Savai R, Schaefer MB, Wilhelm J, Ghofrani HA, Weissmann N, Schudt C, Fleming I, Mayer K, Leiper J, Seeger W, Grimminger F, Schermuly RT.

Circulation. 2011 Mar 22;123(11):1194-204. doi: 10.1161/CIRCULATIONAHA.110.941484. Epub 2011 Mar 7.

PMID:
21382892
4.

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.

Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H.

Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. doi: 10.1016/j.pupt.2010.03.011. Epub 2010 Apr 7. Review.

PMID:
20381629
5.

Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia.

Witzenrath M, Gutbier B, Schmeck B, Tenor H, Seybold J, Kuelzer R, Grentzmann G, Hatzelmann A, van Laak V, Tschernig T, Mitchell TJ, Schudt C, Rosseau S, Suttorp N, Schütte H.

Crit Care Med. 2009 Feb;37(2):584-90. doi: 10.1097/CCM.0b013e3181959814.

PMID:
19114892
6.

Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition.

Dony E, Lai YJ, Dumitrascu R, Pullamsetti SS, Savai R, Ghofrani HA, Weissmann N, Schudt C, Flockerzi D, Seeger W, Grimminger F, Schermuly RT.

Eur Respir J. 2008 Mar;31(3):599-610. Epub 2007 Nov 21.

7.

Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.

Sanz MJ, Cortijo J, Taha MA, Cerdá-Nicolás M, Schatton E, Burgbacher B, Klar J, Tenor H, Schudt C, Issekutz AC, Hatzelmann A, Morcillo EJ.

Br J Pharmacol. 2007 Oct;152(4):481-92. Epub 2007 Aug 20.

8.

Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy.

Schermuly RT, Pullamsetti SS, Kwapiszewska G, Dumitrascu R, Tian X, Weissmann N, Ghofrani HA, Kaulen C, Dunkern T, Schudt C, Voswinckel R, Zhou J, Samidurai A, Klepetko W, Paddenberg R, Kummer W, Seeger W, Grimminger F.

Circulation. 2007 May 1;115(17):2331-9. Epub 2007 Apr 16.

PMID:
17438150
9.

Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock.

Pullamsetti SS, Maring D, Ghofrani HA, Mayer K, Weissmann N, Rosengarten B, Lehner M, Schudt C, Boer R, Grimminger F, Seeger W, Schermuly RT.

Thromb Haemost. 2006 Apr;95(4):720-7.

PMID:
16601845
10.

PKCtheta and PKA are antagonistic partners in the NF-AT transactivation pathway of primary mouse CD3+ T lymphocytes.

Hermann-Kleiter N, Thuille N, Pfeifhofer C, Gruber T, Schäfer M, Zitt C, Hatzelmann A, Schudt C, Leitges M, Baier G.

Blood. 2006 Jun 15;107(12):4841-8. Epub 2006 Mar 2.

PMID:
16514061
11.

Prostanoid pattern and iNOS expression during chondrogenic differentiation of human mesenchymal stem cells.

Mais A, Klein T, Ullrich V, Schudt C, Lauer G.

J Cell Biochem. 2006 Jul 1;98(4):798-809.

PMID:
16440302
12.

Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration.

Pullamsetti S, Krick S, Yilmaz H, Ghofrani HA, Schudt C, Weissmann N, Fuchs B, Seeger W, Grimminger F, Schermuly RT.

Respir Res. 2005 Nov 1;6:128.

13.

Detection of reactive oxygen species in isolated, perfused lungs by electron spin resonance spectroscopy.

Weissmann N, Kuzkaya N, Fuchs B, Tiyerili V, Schäfer RU, Schütte H, Ghofrani HA, Schermuly RT, Schudt C, Sydykov A, Egemnazarow B, Seeger W, Grimminger F.

Respir Res. 2005 Jul 31;6:86.

14.

Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability.

Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Bürger A, Hatzelmann A, Tenor H, Schudt C, Krüll M, Schütte H, Hippenstiel S, Suttorp N.

Blood. 2005 May 1;105(9):3569-76. Epub 2005 Jan 13.

PMID:
15650061
15.

Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.

Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, Weissmann N, Schudt C, Ermert L, Seeger W, Grimminger F.

Circ Res. 2004 Apr 30;94(8):1101-8. Epub 2004 Mar 18.

PMID:
15031263
16.

Zardaverine and aerosolised iloprost in a model of acute respiratory failure.

Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D.

Eur Respir J. 2003 Aug;22(2):342-7.

17.

Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension.

Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F.

Crit Care Med. 2002 Nov;30(11):2489-92.

PMID:
12441759
18.

Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4.

Tenor H, Hedbom E, Häuselmann HJ, Schudt C, Hatzelmann A.

Br J Pharmacol. 2002 Feb;135(3):609-18.

19.

Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity.

Schermuly RT, Krupnik E, Tenor H, Schudt C, Weissmann N, Rose F, Grimminger F, Seeger W, Walmrath D, Ghofrani HA.

Am J Respir Crit Care Med. 2001 Nov 1;164(9):1694-700.

PMID:
11719312
20.

Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.

Hatzelmann A, Schudt C.

J Pharmacol Exp Ther. 2001 Apr;297(1):267-79.

PMID:
11259554
21.

Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis.

Hidi R, Timmermans S, Liu E, Schudt C, Dent G, Holgate ST, Djukanović R.

Eur Respir J. 2000 Feb;15(2):342-9.

22.

Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange.

Schermuly RT, Roehl A, Weissmann N, Ghofrani HA, Schudt C, Tenor H, Grimminger F, Seeger W, Walmrath D.

J Pharmacol Exp Ther. 2000 Feb;292(2):512-20.

PMID:
10640287
23.
24.

Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension.

Schermuly RT, Ghofrani HA, Enke B, Weissmann N, Grimminger F, Seeger W, Schudt C, Walmrath D.

Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1500-6.

PMID:
10556112
25.

Therapeutic potential of selective PDE inhibitors in asthma.

Schudt C, Gantner F, Tenors H, Hatzelmann A.

Pulm Pharmacol Ther. 1999;12(2):123-9. Review. No abstract available.

PMID:
10373395
26.

Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors.

Dent G, White SR, Tenor H, Bodtke K, Schudt C, Leff AR, Magnussen H, Rabe KF.

Pulm Pharmacol Ther. 1998 Feb;11(1):47-56.

PMID:
9802963
27.

Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation.

Gantner F, Götz C, Gekeler V, Schudt C, Wendel A, Hatzelmann A.

Br J Pharmacol. 1998 Mar;123(6):1031-8.

28.

Attenuation by phosphodiesterase inhibitors of lipopolysaccharide-induced thromboxane release and bronchoconstriction in rat lungs.

Uhlig S, Featherstone RL, Held HD, Nüsing R, Schudt C, Wendel A.

J Pharmacol Exp Ther. 1997 Dec;283(3):1453-9.

PMID:
9400021
29.

Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study.

Gantner F, Tenor H, Gekeler V, Schudt C, Wendel A, Hatzelmann A.

J Allergy Clin Immunol. 1997 Oct;100(4):527-35.

PMID:
9338548
31.

Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors.

Gantner F, Küsters S, Wendel A, Hatzelmann A, Schudt C, Tiegs G.

J Pharmacol Exp Ther. 1997 Jan;280(1):53-60.

PMID:
8996181
32.
33.

Automatic leukocyte differentiation in bronchoalveolar lavage fluids of guinea pigs and brown-Norway rats.

Hatzelmann A, Haefner D, Beume R, Schudt C.

J Pharmacol Toxicol Methods. 1996 Apr;35(2):91-9.

PMID:
8729435
34.

Effects of selective and non-selective phosphodiesterase inhibitors on tracheal mucus secretion in the rat.

Wagner U, Bredenbröker D, Fehmann HC, Schwarz F, Schudt C, Von Wichert P.

Eur J Pharmacol. 1996 Mar 18;298(3):265-70.

PMID:
8846825
35.

Hyperpermeability of pulmonary endothelial monolayer: protective role of phosphodiesterase isoenzymes 3 and 4.

Suttorp N, Ehreiser P, Hippenstiel S, Fuhrmann M, Krüll M, Tenor H, Schudt C.

Lung. 1996;174(3):181-94.

PMID:
8830194
36.

Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages.

Tenor H, Hatzelmann A, Kupferschmidt R, Stanciu L, Djukanović R, Schudt C, Wendel A, Church MK, Shute JK.

Clin Exp Allergy. 1995 Jul;25(7):625-33.

PMID:
8521181
37.

Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes.

Tenor H, Staniciu L, Schudt C, Hatzelmann A, Wendel A, Djukanović R, Church MK, Shute JK.

Clin Exp Allergy. 1995 Jul;25(7):616-24.

PMID:
8521180
39.

PDE isoenzymes as targets for anti-asthma drugs.

Schudt C, Tenor H, Hatzelmann A.

Eur Respir J. 1995 Jul;8(7):1179-83. Review.

40.
41.

[Inhibition of histamine liberation in allergic rhinoconjunctivitis in relation to the season].

Räderer I, Haen E, Schudt C, Przybilla B.

Wien Med Wochenschr. 1995;145(17-18):456-8. German.

PMID:
8588365
42.

Activation of adenylate cyclase and phosphodiesterase inhibition enhance neutral endopeptidase activity in human endothelial cells.

Graf K, Kunkel K, Zhang M, Gräfe M, Schultz K, Schudt C, Biroc S, Fleck E, Kunkel G.

Peptides. 1995;16(7):1273-8.

PMID:
8545250
43.

Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors.

Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H.

Am J Physiol. 1994 May;266(5 Pt 1):L536-43.

PMID:
7515580
44.

Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice.

Fischer W, Schudt C, Wendel A.

Biochem Pharmacol. 1993 Jun 22;45(12):2399-404.

PMID:
8392340
45.

Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization.

Rabe KF, Tenor H, Dent G, Schudt C, Liebig S, Magnussen H.

Am J Physiol. 1993 May;264(5 Pt 1):L458-64.

PMID:
7684572
46.

Role of phosphodiesterases in the regulation of endothelial permeability in vitro.

Suttorp N, Weber U, Welsch T, Schudt C.

J Clin Invest. 1993 Apr;91(4):1421-8.

47.

Adenosine receptor-blocking xanthines as inhibitors of phosphodiesterase isozymes.

Ukena D, Schudt C, Sybrecht GW.

Biochem Pharmacol. 1993 Feb 24;45(4):847-51.

PMID:
7680859
49.

Inhibition of IgE-mediated histamine release from human peripheral leukocytes by selective phosphodiesterase inhibitors.

Kleine-Tebbe J, Wicht L, Gagné H, Friese A, Schunack W, Schudt C, Kunkel G.

Agents Actions. 1992 Jul;36(3-4):200-6.

PMID:
1382373
50.

Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai.

Schudt C, Winder S, Forderkunz S, Hatzelmann A, Ullrich V.

Naunyn Schmiedebergs Arch Pharmacol. 1991 Dec;344(6):682-90.

PMID:
1663589

Supplemental Content

Loading ...
Support Center